VIVUS, a biopharmaceutical company developing innovative, next generation therapies addressing unmet needs in obesity, sleep apnea, diabetes, and sexual health. VIVUS’ product Qnexa®, for the treatment of obesity, is awaiting FDA approval. MUSE® (alprostadil), a first generation therapy for the treatment of ED has been commercially available since 1997.